TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05541887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscadine Wine Polyphenol
Description: dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscadine Wine Polyphenol
Description: dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
Study: NCT03649919

Intervention type: OTHER
Description: Patients receive routine diagnostic and treatment medications.

Intervention type: OTHER
Description: Patients receive routine diagnostic and treatment medications.
Study: NCT06089382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8mg orally once a day for 1 year

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: One cycle of TACE postoperatively
Study: NCT04834271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Side-lying external rotation exercise with a dumbbell
Description: Side-lying external rotation exercise with a dumbbell (20-30% 1RM). 2 times per week during 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Side-lying external rotation exercise with a dumbbell with 40% arterial occlusion pressure blood flow restriction
Description: Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 40% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Side-lying external rotation exercise with a dumbbell with 80% arterial occlusion pressure blood flow restriction
Description: Side-lying external rotation exercise with a dumbbell (20-30% 1RM) with 80% arterial occlusion pressure blood flow restriction. 2 times per week during 4 weeks.
Study: NCT05026567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)
Description: Intramuscular injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh
Description: Intramuscular injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area
Description: Intramuscular injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh
Description: Intramuscular injection
Study: NCT04739566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO once daily
Study: NCT06190366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodletting acupuncture at the fossa poplitea
Description: This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodletting acupuncture at the regio glutaea
Description: This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
Study: NCT04943783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
Study: NCT04975958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2025
Description: oral administration
Study: NCT05442112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Patient Message
Description: The intervention is a detailed patient message containing information on strategies for exercise in MS, how to maintain proper sleep, and dietary improvements to maximize health. These strategies are derived from information provided by the National MS Society in their website and covers these topics in greater detail than would normally be addressed in a normal clinic visit. The message also directs patients to the National MS Society website if they would like more information.
Study: NCT05619289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: One-time, oral dose of 300,000 IU of Ergocalciferol administered via 6 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-time, oral dose of 6 inert capsules matched to the active comparator
Study: NCT04593628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect for Caregivers
Description: The STAR Center developed Connect for Caregivers to help improve connectedness among older caregivers of individuals with Alzheimer's Disease and Related Dementias (ADRD). Connect for Caregivers includes three components: (1) psychoeducational materials on the importance of connectedness for health and well-being; (2) a card sort-based 'discussion prioritization tool' that systematizes and routinizes the process of identifying and prioritizing barriers to connectedness; (3) personalized resources to address the identified barriers/targets. We will tailor Connect for Caregivers for Hispanic/Latino and Spanish-speaking caregivers guided by the Selective and Directed Treatment Adaptation Framework. The intervention is given once during the study.
Study: NCT04975958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: infusion
Study: NCT05951283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Closed Loop Insulin Pump
Description: As above
Study: NCT05449457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-Octyl cyanoacrylate
Description: Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
Study: NCT04804891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Therapy
Description: Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
Study: NCT04707638

Intervention type: OTHER
Intervention: No intervention used
Description: No intervention used
Study: NCT05563493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group, Chair-Based Exercise Training
Description: The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group, Breathing exercise
Description: Breathing exercise will be applied to the patients every day they are hospitalized.
Study: NCT05340504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
Study: NCT05172544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-002 YFV
Description: Inactivated YFV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-002 YFV
Description: Inactivated YFV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-002 YFV
Description: Inactivated YFV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-002 YFV
Description: Inactivated YFV vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NaCl 0.9%, Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NaCl 0.9%, Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NaCl 0.9%, Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: NaCl 0.9%, Normal Saline
Study: NCT05305482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated stent
Description: The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
Study: NCT06185855

Intervention type: OTHER
Intervention: Retrospective Ultrasonographic Data Analysis
Description: The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.

Intervention type: OTHER
Intervention: Retrospective Ultrasonographic Data Analysis
Description: The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
Study: NCT05086679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings with 25-30 mm Hg pressure
Description: The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Compression stockings with up to <=10 mm Hg pressure
Description: The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle modification
Description: All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
Study: NCT06354933

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological Soft Signs
Description: Neurological Soft Signs score according to the Heidelberg Manual

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological Soft Signs
Description: Neurological Soft Signs score according to the Heidelberg Manual
Study: NCT05394415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
Study: NCT04968444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back Pain Workshop
Description: Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
Study: NCT05431244

Intervention type: DRUG
Group type: OTHER
Intervention: Antiviral treatment in combination with low-dose gemcitabine
Description: -maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
Study: NCT06416501

Intervention type: OTHER
Intervention: Mode of detection
Description: Mode of detection
Study: NCT04928014

Intervention type: OTHER
Intervention: Schirmer Strip
Description: A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
Study: NCT04836039

Intervention type: OTHER
Intervention: A questionnaire and scales.
Description: Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
Study: NCT06488300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Oral molnupiravir 800mg BD for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days
Study: NCT05292755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) Artificial Tears
Description: A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free, CMC-free Artificial Tears (control)
Description: A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
Study: NCT05208229

Intervention type: DIAGNOSTIC_TEST
Intervention: WB-MRI
Description: Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
Study: NCT05258227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservational Physical Therapy and Proprioceptive Strength Training
Description: The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservational Physical Therapy and Core Instability Strength Training
Description: Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
Study: NCT05003115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).